Medtech companies can learn from Pharma’s evidence-based success to evolve their business strategies, expand market access and thrive.
The landscape of life sciences is profoundly shaped by the strategies companies use to gain market access. Pharma and Medtech, two principal sectors within this space, pursue markedly different paths due to their distinct business models and industry demands. Despite the differences, Medtech companies can potentially leverage strategies from Pharma to enhance their own market penetration and product success. In this article, guest writers Brad Maruca, managing director at Deloitte and former divisional vice president at Abbott Neuromodulation, along with John Jaeger, managing director at Deloitte and expert in commercial strategy, delve into the differences between these two sectors and provide a narrative outlining potential lessons Medtech might draw from Pharma's well-established market access strategies.
Among the many topics covered in detail in the complete downloadable article are:
- Business Models and Market Strategies
- At the core of Pharma's strategy lies a comprehensive engagement model that encompasses policy, payers, patients and clinical guidelines. This sector not only focuses on the initial market entry, but emphasizes the lifetime value of a patient, adopting an annuity model where continuous patient engagement plays a critical role in sustaining revenue. In contrast, Medtech tends to focus on innovation and physician engagement, primarily driving growth through product and procedural innovations. (read more)
- Research & Development and Clinical Approaches
- Pharma's approach to market access is heavily evidence-driven, relying on long-term, structured, and high-risk clinical trials to build a robust case for insurance coverage. This rigorous evidence generation ensures that once a pharmaceutical hits the market, it is backed by indisputable data that secures its place in treatment protocols. Medtech, however, often relies on shorter, iterative development cycles and may not prioritize extensive evidence generation, sometimes leading to challenges in justifying the product's efficacy and value to payers. (read more)
- Utilizing Data and Analytics
- While Pharma has long harnessed the power of big data and advanced analytics to inform everything from drug discovery to market penetration strategies, Medtech has been slower in adopting these resources to their full potential. (read more)
- Collaboration and Pricing Strategies
- Pharma's widespread collaborations with stakeholders across the spectrum—from healthcare providers to research institutions—have fortified its market access strategies. Medtech’s collaborations, though robust with hospitals and clinicians, often miss the broader stakeholder engagement that could drive policy and guideline development. (read more)
Click the button below to download and read the complete "Market Access: What Medtech Can Learn from Pharma" perspective article written by guest writers Brad Maruca, managing director at Deloitte and former divisional VP at Abbott Neuromodulation, and John Jaeger, managing director at Deloitte and an expert in commercial strategy,